Clinical Trials in Florida

Showing 10661-10680 of 10,975 trials

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

NCT00636740

The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy. The effects will be monitored on a weekly basis by measuring various markers of bone metabolism. Patients to be enrolled will be those who have not received any previous bisphosphonate therapy. The study will be carried out on prostate cancer patients who are no longer on hormone therapy. Treatment in the study will be for a 2-month period.

Hormone-Refractory Prostate Cancer

Merrion Pharmaceuticals, LLC30 participantsStarted Feb 2008

Birmingham, Alabama, United States • Lake City, Florida, United States • Lakeland, Florida, United States +10 more locations

COMPLETEDPhase 349 miles

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

NCT00329446

The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Generalized Anxiety Disorder

AstraZeneca800 participantsStarted Apr 2006

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +60 more locations

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Find Trials by Condition in Florida

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee

Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Carmustine in Treating Patients With Recurrent Malignant Glioma

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

CPG 7909 Injection in Non-Small Cell Lung Cancer

Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1

The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder